Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
  • Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202;R-Roscovitine), administered twice daily for 7-days every 21 days.

Thumbnail
View/Open
Published version (173.4Kb)
ICR Author
Raynaud, Florence
Workman, Paul
Kaye, Stanley Bernard
Author
Benson, C
White, J
De Bono, JS
O'Donnell, A
Raynaud, F
Cruickshank, C
McGrath, H
Frenz, L
Rose, F
Walton, M
Workman, P
Kaye, S
Show allShow less
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/496
Collections
  • Cancer Therapeutics
  • Closed Research Teams
Research team
Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
Medicine Drug Development Unit (Kaye)
Language
eng
Date accepted
2006-11-07
License start date
2006-11-07
Citation
Br J Cancer. 2007, Jan 15, 1 (96), pp. 29 - 37

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.